Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma

Autor: Elizabeth Garrett-Mayer, Robert K. Stuart, Luciano J. Costa, Jagadish Kummetha Venkata, Kiwana Gibbs, Woodrow J. Coker, Besim Ogretmen, Jin H. Song, Yubin Kang, Zhuang Wan, Houjian Cai, Terri Matson, Ningfei An, Charles D. Smith
Rok vydání: 2014
Předmět:
Proteasome Endopeptidase Complex
Pathology
medicine.medical_specialty
Stromal cell
Pyridines
Immunology
Cell
Down-Regulation
Adamantane
Antineoplastic Agents
Apoptosis
Mice
SCID

Biology
Biochemistry
Proto-Oncogene Proteins c-myc
Mice
chemistry.chemical_compound
Mice
Inbred NOD

immune system diseases
Cell Line
Tumor

hemic and lymphatic diseases
medicine
Animals
Humans
RNA
Messenger

RNA
Neoplasm

Enzyme Inhibitors
RNA
Small Interfering

Multiple myeloma
Cell Proliferation
Mice
Knockout

Lymphoid Neoplasia
Sphingosine
Caspase 3
Cell growth
Sphingosine Kinase 2
Cell Biology
Hematology
medicine.disease
Xenograft Model Antitumor Assays
Phosphotransferases (Alcohol Group Acceptor)
medicine.anatomical_structure
Proto-Oncogene Proteins c-bcl-2
chemistry
Cancer cell
Cancer research
Myeloid Cell Leukemia Sequence 1 Protein
Multiple Myeloma
Zdroj: Blood. 124:1915-1925
ISSN: 1528-0020
0006-4971
DOI: 10.1182/blood-2014-03-559385
Popis: Sphingolipid metabolism is being increasingly recognized as a key pathway in regulating cancer cell survival and proliferation. However, very little is known about its role in multiple myeloma (MM). We investigated the potential of targeting sphingosine kinase 2 (SK2) for the treatment of MM. We found that SK2 was overexpressed in MM cell lines and in primary human bone marrow (BM) CD1381 myeloma cells. Inhibition of SK2 by SK2- specific short hairpin RNA or ABC294640 (a SK2 specific inhibitor) effectively inhibited myeloma cell proliferation and induced caspase 3–mediated apoptosis. ABC294640 inhibited primary human CD1381 myeloma cells with the same efficacy as with MM cell lines. ABC294640 effectively induced apoptosis of myeloma cells, even in the presence of BM stromal cells. Furthermore, we found that ABC294640 downregulated the expression of pS6 and directed c-Myc and myeloid cell leukemia 1 (Mcl-1) for proteasome degradation. In addition, ABC294640 increased Noxa gene transcription and protein expression. ABC294640, per se, did not affect the expression of B-cell lymphoma 2 (Bcl-2), but acted synergistically with ABT-737 (a Bcl-2 inhibitor) in inducing myeloma cell death. ABC294640 suppressed myeloma tumor growth in vivo in mouse myeloma xenograft models. Our data demonstrated that SK2 provides a novel therapeutic target for the treatment of MM.This trial was registered at www.clinicaltrials.gov as #NCT01410981.
Databáze: OpenAIRE